Claritev Corporation Class A Common Stock (CTEV)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits and generate cash, and Claritev does not yet fit that description. It sells data analytics, payment, and revenue-integrity services to healthcare; revenue is real, at $965.4 million in fiscal year 2025, ended 2025-12-31, and $257.5 million in fiscal Q2 2026, the quarter ended 2026-06-30. That latest quarter was up from $241.6 million in fiscal Q2 2025, the quarter ended 2025-06-30, so the top line is growing. But the bottom line is ugly: fiscal year 2025 net income was -$284.3 million, and fiscal Q2 2026 net loss was -$59.2 million. FairStock calculates trailing free cash flow of -$17.9 million, an Altman Z-score of -0.63, and ROCE of 1.19%. Those are not the marks of a durable moat or financial strength. The company has lost money in each of the last four years, so FairStock assigns no Peter Lynch category. At the 2026-10-13 close of $23.72, market cap is $402 million; FairStock's negative P/E of -1.40 and -4.5% FCF yield mean there are no earnings to value. Its EV/EBITDA of 10.61 might look moderate if EBITDA is stable, but with net losses and a Piotroski F-score of 6/9, it is not a bargain I can underwrite on numbers alone. FairStock shows revenue growth of 5.77% and profit growth of -3.14%. Until losses shrink and cash turns positive, this is a speculation on a turnaround, not a Graham-style value.

In plain English: Claritev sells data and payment technology to healthcare companies. It has lost money for years, and its latest quarter was still unprofitable even though revenue rose a little. At the 2026-10-13 close of $23.72, the price does not look cheap because the company has no profits and is burning cash.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer